TXMD

TherapeuticsMD, Inc.
CAPPED RATING

TherapeuticsMD Inc is a women\'s health care company focused on creating and commercializing products targeted exclusively for women. It is engaged in pre-commercialization activities for advanced hormone therapy pharmaceutical product.

TherapeuticsMD, Inc. (TXMD) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (D-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B
Factor Score 3.3 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 5.3
EV / EBITDA -13.2
Rev Growth YoY -8.7%
Gross Margin N/M
Price Return 3M -7.0%
Price Return 12M 11.3%
Catalyst Signal 0.00
Market Cap $21.6M
TTM Revenue $3.3M
Price / Sales 6.6
ROE -1.1%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B (3.3) D- (1.1) B (3.3) B- (2.9) C+ (2.6) C+ (2.7)
2026-11-08 B (3.3) D- (1.1) B (3.4) B- (3.0) C+ (2.6) C+ (2.7)
2026-11-01 B (3.4) D (1.2) B (3.3) B- (2.9) C+ (2.7) C+ (2.7)
2026-10-25 B (3.3) D- (1.1) B (3.4) C+ (2.7) C+ (2.6) C+ (2.6)
2026-10-18 B (3.3) D- (1.1) B (3.3) C+ (2.8) C+ (2.6) C+ (2.6)
Page 1 of 3